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Abstract Ongoing angiogenesis has been shown to pos-
sess immune suppressive activity through several mecha-
nisms. One of these mechanisms is the suppression of
adhesion receptors, such as intercellular adhesion mole-
cule-1, vascular cell adhesion molecule-1 and E-selectin—
adhesion molecules involved in leukocyte interactions—on
the vascular endothelium. This phenomenon, when happen-
ing to the tumor endothelium, supports tumor growth due to
escape from immunity. Since angiogenesis has this immune
suppressive eVect, it has been hypothesized that inhibition
of angiogenesis may circumvent this problem. In vitro and
in vivo data now show that several angiogenesis inhibitors
are able to normalize endothelial adhesion molecule
expression in tumor blood vessels, restore leukocyte vessel
wall interactions, and enhance the inXammatory inWltrate
in tumors. It is suggested that such angiogenesis inhibitors
can make tumors more vulnerable for the immune system
and may therefore be applied to facilitate immunotherapy
approaches for the treatment of cancer.
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Introduction
Immune cells are circulating and recirculating cells, hunt-
ing for antigens that are non-self thereby trying to get rid
of agents such as non-self molecules, microorganisms,
(virally) infected host cells, and otherwise altered host
cells. Tumor cells are genetically mutated cells that can be
recognized and eliminated by the immune system. This
recognition and elimination is apparently an extremely
eYcient process, given that facts that (1) in an average per-
son 70,000 billion cells are continuously exposed to multi-
ple mutating environmental factors, such as carcinogens in
food, Wne dust, sunlight, and (cosmic) radiation, (2) it has
been estimated that on average 10,000 DNA repair activi-
ties are necessary in each cell every day, and (3) that cancer
only develops in a minority of people.
Despite the eYciency of the immune system, cancer can
develop due to mechanisms evolved by tumors to escape
from surveillance of immune cells. These mechanisms are
multiple and several of them have been discovered over
the last decades. Tumor antigens may not be speciWc
enough for discrimination from normal host cells. Toler-
ance may be induced by insuYcient stimulation of
co-stimulation of accessory molecules on lymphocytes.
Tumors may downregulate MHC molecules to escape
from (cytotoxic) T cell recognition. In addition, tumors
may produce immune inhibitory molecules such as IL-10,
TGF- or prostaglandins. Alternatively, activation of reg-
ulatory T cells that suppress the speciWc immunity may be
too eYcient. There is also another means of tumor escape
from immunity which is based on changes in the tumor
vasculature. Tumors are able to down regulate adhesion
molecules on the vascular endothelium. These are not the
adhesion molecules that are involved in the interaction
with the extracellular matrix—these are often induced
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during angiogenesis—but the endothelial adhesion molecules
that are necessary for interactions with leukocytes, such as
granulocytes, macrophages, NK cells and lymphocytes.
The suppression of these adhesion molecules, and thereby
the adhesive properties of the endothelium, was found to
be caused by exposure of endothelial cells to angiogenic
growth factors produced by the tumor. Angiogenesis is
required for the outgrowth of tumors, and plays a role in
metastasis formation, and outgrowth as well [1–4]. Angio-
genesis is intricately regulated by stimulators and inhibi-
tors. In normal tissues angiogenesis is switched oV, but in
tumors the process is stimulated through production of
cytokines such as vascular endothelial cell growth factors
(VEGFs) and Wbroblast growth factors (FGFs) by tumor
cells. It has been known for long time that tumor blood
vessels have suppressed expression of adhesion molecules
[5–8]. Evidence has been building that tumor cells are
involved in the eYcient downregulation of these adhesion
receptors, through the production of angiogenic growth
factors, as is described in this review.
Angiogenic growth factors make endothelial cells 
unresponsive to inXammatory signals–the discovery 
of tumor endothelial cell anergy
In an eVort to investigate ways to improve immunotherapy
approaches for the treatment of cancer, it was found that
endothelial cells isolated from human tumors express
signiWcantly lower levels of adhesion molecules that are
involved in leukocyte–vessel wall interactions, such as
intercellular adhesion molecule-1 (ICAM-1), vascular cell
adhesion molecule-1 (VCAM-1), E-selectin and CD34. As
this feature may provide tumors with an immuno-privileged
status, it was investigated what the mechanism of this lack
of adhesive properties of tumor endothelium was. It was
found that the disappearance of these adhesion molecules is
due to exposure to tumor derived angiogenic growth factors
[9–12]. Since ICAM-1 is the most important adhesion mol-
ecule involved in the extravasation of leukocytes into the
surrounding tissue—it has been demonstrated to be both
required as well as suYcient for the process of extravasa-
tion—most studies have been focused on the expression of
ICAM-1. In Fig. 1a the response of umbilical vein endothe-
lial cells (HUVECs) to bFGF exposure is shown. Both
bFGF and VEGF, which are the strongest mitogenic factors
for endothelial cells, but also other growth factors, such as
epidermal growth factor (EGF) and placental growth factor
(PlGF) were found to be able to downregulate ICAM-1—
though to a lesser extent—on the surface of endothelial
cells in vitro (Fig. 1b).
Not only were these adhesion molecules absent in tumor
endothelial cells, it was also discovered that endothelial
cells exposed to tumor derived growth factors are unre-
sponsive to inXammatory cytokines such as interleukin-1,
interferon-gamma, and tumor necrosis factor-. These
inXammatory cytokines normally induce an adhesive phe-
notype in endothelium by induction of adhesion molecules,
but angiogenic endothelial cells are refractory to these
signals. The lack of leukocyte adhesion receptors and the
unresponsiveness to inXammatory signals has been termed
tumor endothelial cell anergy [9,  10]. This anergy ulti-
mately results in abrogation of immune surveillance and
escape of the tumor from immunity, allowing undisturbed
outgrowth and metastasis formation.
Despite the growing body of research that describes sup-
pression of adhesiveness of endothelial cells during angio-
genesis, there are also reports describing that angiogenesis
may also be involved in induction of adhesion molecules
and leukocyte–vessel wall interactions. Melder et al. [12]
described that VEGF has an opposite function as bFGF,
stimulating expression of ICAM-1 and inducing adhesive-
ness. In another study VEGF transgenic mice were found to
have an increased microvessel density and an enhanced
Fig. 1 Angiogenic stimulation 
of endothelial cells suppresses 
ICAM-1 expression. a Suppres-
sion of ICAM-1 on HUVEC 
after exposure to 10 ng/ml 
bFGF. Maximal induction of 
proliferation (3H-thymidine 
incorporation) approximately 
100–120% at day 3. 
b Suppression of ICAM-1 
expression in HUVEC by 
diVerent growth factors, in a 
3d a y  c u l t u r eCancer Immunol Immunother (2008) 57:1553–1558 1555
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leukocyte rolling and adhesion in the skin [13]. This appar-
ent discrepancy might have an explanation in the sequence
of events. It is shown in Fig. 1a that endothelial cells
exposed to mitogenic signals Wrst upregulate ICAM-1 after
which a marked and prolonged suppression occurs. It is
unknown why endothelial cells Wrst upregulate the expres-
sion, but it may be related to the function of ICAM-1 as a
receptor for extracellular matrix components, such as
hyaluronic acid [14]. It is known that receptors for matrix
interactions such as the integrins are induced during angio-
genesis to prepare the cells for migration into the direction
of the angiogenic stimulus. It is feasible that ICAM-1 has a
dual function. Involvement in endothelial cell migration
during early stages of cell activation, and suppression of
leukocyte interaction during later stages. That the induction
of ICAM-1 is not a commonality among angiogenic growth
factors is suggested by the fact that other angiogenic
growth factors are able to suppress this stimulatory activity
of VEGF [15].
In my view an inverse relationship between angiogenesis
and adhesiveness is the most logical scenario, also because
of the general cell biology principle that a cell preparing for
growth will de-diVerentiate and suppress other activities,
while diVerentiation to an adhesive phenotype may be more
logically associated with slower growth. The inverse rela-
tionship with angiogenesis and inXammatory processes was
also observed in a study where inXammatory cytokines
were found to inhibit the proliferation of endothelial cells.
A key molecule in this process was found to be guanylate
binding protein-1 [16, 17].
Several mechanisms have been shown to be involved in
the downregulation of endothelial cell adhesion molecules.
One of these was discovered in an eVort to identify the
epigenetic component in tumor angiogenesis [18]. By phar-
macological inhibition of epigenetic regulatory mecha-
nisms such as promoter hypermethylation and histone
deacetylation, it was unexpectedly found that ICAM-1 was
among the genes that were most eYciently re-induced [19,
20]. Indeed, the ICAM-1 gene contained CpG islands.
These are CG-rich foci in the sequence that allow methyla-
tion of the promoter DNA, which may result in silencing of
the gene. Interestingly, it was not the promoter methylation
component, but rather the histone deacetylation related
mechanism that was responsible for the absence of ICAM-1
in tumor endothelium [19].
Another mechanisms of angiogenic growth factor medi-
ated induction of endothelial cell anergy was through the
sustained activation of p38 MAPK and subsequent inhibi-
tion of the transcription factor NFkB, which is under nor-
mal conditions heavily involved in the upregulation of
ICAM-1 [21]. The latter was only demonstrated for bFGF
but the results are highly suggestive for a commonality
among angiogenic growth factors for this activity.
Although these mechanisms do show some insight as to
how EC anergy is regulated, they do not exclude other
additional explanations.
Ongoing angiogenesis prevents leukocyte–vessel wall 
interactions and leukocyte inWltration
To investigate whether the angiogenesis mediated signals
have the expected impact on the function of endothelial
cells, in vitro leukocyte adhesion assays, and in vivo intra-
vital microscopy studies were performed. These studies
indicated that indeed exposure of endothelial cells to
individual recombinant angiogenic growth factors reduce
adherence of leukocytes under static conditions [9] and
both rolling and Wrm adhesion under sheer stress condi-
tions [22]. In vivo studies of implantation of slow-release
pellets containing recombinant bFGF or VEGF showed
that the mere exposure to these factors dramatically
reduces adhesive properties of endothelial cells also after
stimulation with TNF- [ 23]. In several in vivo tumor
models in mice it was shown that leukocyte rolling as well
as Wrm adhesion to the vessel wall in the tumor vasculature
is markedly reduced [12, 24] (Fig. 2). These studies were
carried out in small tumors grown in the ears of athymic
nude mice, in order to be able to perform intravital micros-
copy in a non-invasive way. This technique allowed us to
demonstrate that also blood vessels outside but close to the
tumor, are under regulation of tumor-derived angiogenic
growth factors. It was even demonstrated that leukocyte–
vessel wall interactions in general are hampered systemi-
cally in mice carrying a large tumor on the Xank [24]. It is
tempting to speculate that the latter result may account for
the known impairment of immune functions in patients
with cancer. 
The thus developed theme of the relationship between
angiogenesis and the immune system was further substanti-
ated in human tumors. The Wrst question that arose was
whether there would be an angiogenesis based explanation
for the diVerence between breast cancer patients with ductal
carcinoma and with medullary carcinoma. The latter group
of patients, which is a rather small group with a slightly
better prognosis, is characterized by tumors with increased
amounts of inWltrated leukocytes in the tumor, when com-
pared to tumors of patients with ductal carcinomas. We
found indeed a more pronounced proWle of angiogenic fac-
tors in ductal carcinomas. By real-time PCR assessment,
VEGF-A, bFGF, PlGF, and angiopoietins-1,-2, and -4 were
all more strongly expressed by factor of 5–20. Interest-
ingly, the largest diVerences were present in the expression
levels of VEGF-C and -D, with a higher expression (200–
250 times) in ductal carcinomas. It was shown that both
VEGF-C and -D can synergize with other angiogenic1556 Cancer Immunol Immunother (2008) 57:1553–1558
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growth factors such as bFGF, to downregulate ICAM-1
[25]. Also in tumor tissues of patients with colorectal carci-
noma a negative correlation was found between expression
of VEGF or the number of proliferating endothelial cells as
measure of ongoing angiogenesis and leukocyte inWltration
[26]. Kaplan–Meier analysis suggests that prognosis can
seriously improve when based on both angiogenesis and
leukocyte inWltration. A similar relationship was found by
others in ovarian carcinoma. Zhang et al. [27] found that
the number of inWltrated T cells is a prognostic value pre-
dicting longer survival. In the same study it was found that
this parameter was inversely correlated to the expression of
VEGF.
Inhibition of angiogenesis restores adhesiveness 
of tumor endothelium and leukocyte inWltration 
in tumors
The immune-suppressive eVects of ongoing angiogenesis
made us hypothesize those inhibitors of angiogenesis may
revert endothelial cell anergy and increase leukocyte inWl-
tration in tumors, thereby enhancing the vulnerability of
tumors to the immune system. It was found that a broad
array of angiogenesis inhibitors—among which endostatin,
anginex, anti-VEGF antibodies as well as chemotherapeutic
compounds with claimed angiostatic activity—have the
capacity to normalize the expression of adhesion molecules
on tumor endothelial cells, as well as to normalize their
responsiveness to inXammatory cytokines both in vitro [28,
29] and in vivo [30]. It has been demonstrated that treat-
ment of tumor bearing mice with angiogenesis inhibitors
stimulates leukocyte inWltration into the tumor. It can be
argued that it is unknown whether the leukocytes present
inside a tumor—either within the tumor cell nests or in the
tumor stroma—or around the tumor really contribute to the
anti-tumor response or are considered only “tumor observ-
ing leukocytes”. The current discussion on the beneWt of
leukocytes inside a tumor involves the presence of mono-
cytes and macrophages. It has been demonstrated that the
presence of these cells induces growth signals in tumor
cells and stimulates angiogenesis [31,  32], leading to a
worse prognosis. Current research is performed to demon-
strate the contribution of angiogenesis inhibitors to this
immune response. Since an enhanced number of leukocytes
in or around the tumor is most often correlated to a beneW-
cial prognosis, it is most likely that inWltration is a sign of
an ongoing anti-tumor immune response.
Angiogenesis inhibition has been demonstrated to be
especially of beneWt in combination with other anti-cancer
strategies. In early mouse studies it was already noted that
angiogenesis inhibition when combined with chemotherapy
has excellent anti-tumor activity [33]. Next to many expla-
nations for synergism, one of the best explanations is the
phenomenon of vessel normalization. Upon exposure to
angiogenesis inhibitors blood vessels normalize from tumor
induced enhanced permeabilization and tortuous morphol-
ogy. This leads to normalization of the interstitial pressure
which leads to enhanced sensitivity of tumor cells to che-
motherapeutic agents [34]. It is therefore not unexpected
that the Wrst approval of an angiogenesis inhibitor, Avastin,
was for use against colorectal cancer in combination with
intravenous 5-Xuorouracil-based chemotherapy. Also other
anti-cancer strategies, such as radiation therapy, have
Fig. 2 Induction of ICAM-1 leads to leukocyte–vessel wall interac-
tions and tumor inWltration. a Suppression of ICAM-1 on HUVEC
after incubation in 10 ng/ml bFGF. b Expression of ICAM-1 on freshly
isolated endothelial cells (CD31 double staining) from normal human
renal tissue (upper panel) renal cell carcinoma tissue (lower panel).
c Video stills of leukocyte–vessel wall interactions in normal tissue
(upper panel), B16F10 mouse melanoma tumor tissue (middle panel)
and tumor tissue after treatment with an angiogenesis inhibitor (angin-
ex, 10 mg/kg/day, 2 weeks, lower panel). Video movies of these
experiments can be viewed at www.angiogenesis.nl.  d Leukocyte
inWltration (and microvessel density. e In B16F10 melanoma tumors
(upper panels) and in tumor treated with the angiogenesis inhibitor
anginex (lower panels)Cancer Immunol Immunother (2008) 57:1553–1558 1557
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shown to improve by angiogenesis inhibition [35]. The
results as described in the current paper suggest that an
immunotherapy approach against cancer should also sig-
niWcantly beneWt from angiostasis. The development of
immunotherapy strategies is currently very rapid. While
until the 1980s immunotherapy was mostly treatment with
recombinant cytokines (e.g., interleukin-2, interferon), after
that strategies using leukocyte transfer or stem cell trans-
plantations, and vaccination strategies using peptides and
antigen loaded dendritic cells (DC) were developed. It is
fundamental to any form of immunotherapy that an induced
immune response leads to the generation of tumor speciWc
leukocytes that are able to reach the tumor cells through the
tumor vasculature. It is highly expected that anti-angiogen-
esis therapy may improve future immunotherapy regimens.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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